How to classify this AlanR treatment for colds. The main problem is that it is just a home treatment with no credentials. It works for me and my friends. Thousands of people must have tried it. Over 6,000 Indonesians, about 1700+ people from each of the countries, Hong Kong, the USA, and Germany for example, almost 18,000 in total, have visited the site. To date, nobody has commented, good or poor. What is needed is some official standing, a simple clinical trial to determine the efficacy.
What the treatment does is kill the virus in the early stages. It is an enhancement of the very ancient fever immune response using the three parameters heat, humidity and time. The unique part is to temporarily convert the nasal cavity and throat, from a place where the virus replicates, to a virus-killing zone. The process takes about 1.5 - 2 hours. The equivalent that pharmaceutical companies are bringing to market is 3 targeted pills a day for 5 days.
What I am proposing is that a simple trial using my treatment could be a university medical student-level group project for a term paper. It would need to have the blessing of a professor that is comfortable working outside the box and a student to champion the project. The primary thesis could be that most cold viruses have a sensitivity limit (mortality) in the range of 37.5 to 39 0C and relative humidity of > 95% in vivo (references below). To my knowledge, this has never been done. There could also be a published paper by the prof and students. This project would be a hands-on medical research experience and a bonus to any student’s resume.
There is also a very low risk of applying the treatment if the rules are followed. There are no drugs, no injections, no pain, and no expensive equipment necessary. The required materials are nose clips or medical tape, hand sanitizer (for cleaning the oily nose surface), temperature measuring devices, and PPE supplies, except for the nose clips the above are readily available at most universities. Side effects: a clear nasal cavity, a quick recovery (depending on how much damage has been done by the virus).
I have sent notes to WHO, NIH, CDC, Mayo Clinic, The UN, Canada Health, 5 Universities, the Health department of 5 provinces, and several clinical doctors. I have had 3 replies, 2 were for permissions to reference their papers. So far, there have been no debunks that I know of, but the data from my website suggests many referrals.
It is time for me to move on to thoughts about skiing and leave COVID19 in the background. I live in a small valley beside a salmon stream. Eagles are patrolling the stream looking for salmon remains from spawning. Both deer and black bears wander through the two-hector lot on occasion. Snow is starting to collect higher up on the mountains to the west. I’ve signed up again as a volunteer ski instructor with the adaptive snow school group and the mountain opens for skiing on Dec. 10.
Me, Alan Robb, I’ve been around a university for 11 years as a student and 10 years as a prof., a research centre for 8 years, and a consultant for 25 years. If interested please contact me through my email email@example.com . I live on the west coast for 7 mo and 5 mo in central Canada.
Some References (revised 01- Nov 23/21)
1. - Why is temperature sensitivity important for the success of common respiratory viruses? Eccles R., Rev Med Virol. 2020;e02153.
2. -Body temperature and host species preferences of SARS-CoV-2.
Uzoigwe, Chika Edward https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30424-9/pdf
3. -The Effects of Temperature and
Relative Humidity on the Viability of the SARS
K. H. Chan, et al,
4. -Role of fever and ambient temperature in COVID-19
Muhammad Hamdan Gul,a Zin Mar Htun,b and Asad Inayatc
5. -Animal and translational models of SARS-CoV-2 infection and COVID19 M. D. Johansen1, et al,
Mucosal Immunology (2020) 13:877–891;
6. -Fever and the thermal regulation of immunity: the immune system feels the heat
Sharon S. Evans, Elizabeth A. Repasky, and Daniel T. Fisher HHS Author Manuscripts PMC4786079
7. Protective Facemask Impact on Human Thermoregulation: An Overview
David Tyrrell, Ian Barrow, James Arthur
BMJ 002231-0020 1989
Marc Cohen, Extreme wellness Institute, Melbourne, VIC, Australia
Farhad Memarzadeh, PhD, PE